4//SEC Filing
Schwabe Stefan K.F. 4
Accession 0001104659-20-135882
CIK 0001356576other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 8:20 PM ET
Size
23.1 KB
Accession
0001104659-20-135882
Insider Transaction Report
Form 4
Schwabe Stefan K.F.
Executive Vice President R&D
Transactions
- Exercise/Conversion
Common Stock
2020-12-14$9.13/sh+50,000$456,500→ 52,772 total - Exercise/Conversion
Common Stock
2020-12-14$12.98/sh+3,653$47,416→ 56,425 total - Sale
Common Stock
2020-12-14$22.00/sh−3,653$80,369→ 2,772 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-12-14−3,653→ 46,347 totalExercise: $12.98Exp: 2026-03-01→ Common Stock (3,653 underlying) - Sale
Common Stock
2020-12-14$21.86/sh−50,000$1,092,895→ 6,425 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2020-12-14−50,000→ 0 totalExercise: $9.13Exp: 2025-03-03→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.5500 to $22.0300, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.0000 to $22.0100, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The option vests in four equal annual installments beginning on March 3, 2016.
- [F5]The option vests in four equal annual installments beginning on March 1, 2017.
Issuer
SUPERNUS PHARMACEUTICALS, INC.
CIK 0001356576
Entity typeother
Related Parties
1- filerCIK 0001557657
Filing Metadata
- Form type
- 4
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 8:20 PM ET
- Size
- 23.1 KB